Biogen Believes Biologics Production Capacity Will Lure Partners
Executive Summary
Biogen believes its investments in protein manufacturing capacity will give it an advantage in upcoming years in the search for new product partners in the biotech sector.
You may also be interested in...
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.
Elan Developing Antegren For Chronic MS; Quarterly Sales Up 50%
Elan will pursue development of Antegren (natalizumab) humanized monoclonal antibody for chronic treatment of multiple sclerosis, the company announced July 26.